Individual BE Replicate Study Design To Be Analyzed Over Two Years By FDA
Executive Summary
FDA is planning to conduct a two-year evaluation of its recommended replicate design method to determine whether a transition away from average bioequivalence criterion and towards individual and population BE criteria should occur.